Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia

Immunotherapy has without question revolutionized the treatment of both hematologic and solid malignancies. Over the last several years novel strategies are being developed to incorporate these groundbreaking therapies into the care of patients with AML. Here we present an overview of the recent developments in immunotherapy for AML with a focus on biomarkers of response. Topics reviewed include antibody drug conjugates, BiTEs, DARTs, checkpoint inhibitors, and cellular therapy as well as the development of biomarkers predictive of response in each class.

Automated summary

This article provides an overview of recent advancements in immunotherapy for AML, focusing on biomarkers of response. The topics covered include antibody drug conjugates, BiTEs, DARTs, checkpoint inhibitors, cellular therapy, and the development of predictive biomarkers for response in each class.